S. 2406 · 118th Congress · Health
PBM Oversight Act of 2023
- IntroducedJul 20, 2023 Done
- CommitteeDied Jan 3, 2025 Stopped here
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires prescription drug plan (PDP) sponsors under the Medicare prescription drug benefit to report certain information about the involvement of affiliated committees in decisions about formularies.
Specifically, PDP sponsors that use formularies must report to the Centers for Medicare & Medicaid Services the names and descriptions of committees that are affiliated with the PDP sponsor, or a contracted pharmacy benefit manager, that are authorized to change initial recommendations of the pharmacy and therapeutic committee about formularies. PDP sponsors must also report any formulary changes that were made by an affiliated committee and provide justifications for these decisions.
The Government Accountability Office must report on the use of these types of committees with respect to formularies under the Medicare prescription drug benefit, including decision-making trends.
Congressional Research Service · summary of “Introduced in Senate” version · Jul 20, 2023
Who lobbies on it
2 organizations · 4 filings · Q3 2023–Q4 2024One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Care Management Association
3 of 6 quarters
“Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits S.652 - Safe Step Act S.1038 - Drug Price Transparency in Medicaid Act S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act S.1217…”
-
Cigna Corporation
1 of 6 quarters
“Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid…”
Organizations that named S. 2406 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
2 actions · newest first- Jul 20, 2023Read twice and referred to the Committee on Finance.
- Jul 20, 2023Introduced in Senate